Advancing Bold Therapies for Neuronal Health, Mark Litton, President & CEO, Athira Pharma
Synopsis:
Mark Litton, Ph.D., is the President and CEO of Athira Pharma, a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration for those suffering from Alzheimer’s, Parkinson’s disease, dementia, and more. Mark talks about being a CEO for the first time and what he’s learned. He discusses how the biotech ecosystem and its ability to raise capital for companies has changed over the last couple of years and how that’s informing how he’s operating at Athira. He talks about fundraising strategy and how he communicates with team members who perhaps haven’t been involved in fundraising cycles and value creation at biotech before. Finally, he shares how he thinks about business development and his approach to partnerships.
Biography:
Mark is President and CEO of Athira Pharma, a position he has held since October 2021. Previously, he served as Athira’s COO since July 2019. Prior to joining Athira, Mark served as the President and COO of Alpine Immune Sciences, Inc. Prior to that he spent more than 14 years at Alder Biopharmaceutical Inc., a publicly traded biopharmaceutical company, which was acquired by Lundbeck A/S. As co-founder and CBO, Mark helped build the business and oversaw finance, investor relations, deal making, business development, alliance management, human resources, and overall corporate strategy. While at Alder, Mark was directly responsible for raising over ~$1B in equity capital and led negotiations for numerous corporate alliances between biotech and pharmaceutical companies.
Mark has a PhD in immunology from Stockholm University, an MBA from Santa Clara University and a BA in Biochemistry and Molecular Biology from UC Santa Cruz.